EAGAN, MN – September 14, 2006 – A U.S. Federal District Court recently
granted Biothera's petition to expand its patent infringement lawsuit
against Biotec Pharmacon ASA to include seven additional patents. Biothera
asserts Biotec's primary compound in pharmaceutical development infringes
these patents.

The court also allowed the Massachusetts Institute of Technology (MIT) to
join the lawsuit as a co-plaintiff in its role as patent-owner of certain
patents that are part of the litigation and that are exclusively licensed to
Biothera.

Biothera's lawsuit originally asserted that the Norwegian company was
violating seven patents protecting its particulate beta glucan compounds
used in nutritional supplements, functional foods and animal nutrition.
Analysis of Biotec's Soluble Beta Glucan (SBG) during the discovery period
prompted Biothera to petition the court to amend the lawsuit.

"The court's ruling is significant," said Richard G. Mueller, Biothera
president and chief executive officer, "because it provides Biothera with
the opportunity to protect both our pharmaceutical and healthcare businesses
from patent-infringing products and compounds."

Biothera has more than 40 U.S. patents and patents pending, as well as
additional patents in more than 20 countries, protecting the matter of
composition, manufacturing and use of beta glucan derived from yeast
(Saccharomyces cerevisiae).

Biothera has successfully defended its patents against infringement in four
previous lawsuits.

About Biothera, the Immune Health Company
Biothera is a biotechnology company dedicated to improving immune health.
The company's primary focus is developing pharmaceuticals that engage the
immune system to fight cancer. In addition, compounds are also in
development to facilitate immune system recovery after damage from
chemotherapy or acute radiation exposure. Biothera also manufactures and
markets food-grade ingredients that support healthy immune function to the
nutritional supplement, functional food, cosmetic and animal nutrition
markets.

Contact:
David Walsh
VP, Communications
Biothera, the Immune Health Company
651-256-4606
dwalsh@biotherapharma.com